Graft rejection - endogenous or allogeneic?

Immunology

Volumn 136, Issue 2, 2012, Pages 123-132

  Critchley, William R ^a   Fildes, James E ^a,b  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Innate immunity; Novel biological therapies (anti cytokines etc.); T cells; Toll receptors toll like receptors; Transplantation

Indexed keywords

ALLOANTIGEN; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA;

ADAPTIVE IMMUNITY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; GRAFT REJECTION; HUMAN; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TH17 CELL; TISSUE INJURY;

ANIMALS; ANTIGENS; CYTOKINES; GRAFT REJECTION; HUMANS; LEUKOCYTES; MICE; RATS; STRESS, PHYSIOLOGICAL; T-LYMPHOCYTES;

EID: 84860238596     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2012.03560.x     Document Type: Review

References (100)

1. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999; 5:1249-55.
2. Rock KL, Kono H. The inflammatory response to cell death. Annu Rev Pathol 2008; 3:99-126.
3. Raoof M, Zhang Q, Itagaki K, Hauser CJ. Mitochondrial peptides are potent immune activators that activate human neutrophils via FPR-1. J Trauma 2010; 68:1328-32, discussion 1332-24.
4. Zhang Q, Raoof M, Chen Y et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010; 464:104-7.
5. He H, Stone JR, Perkins DL. Analysis of robust innate immune response after transplantation in the absence of adaptive immunity. Transplantation 2002; 73:853-61.
6. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425:516-21.
7. Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001; 13:114-9.
8. Pockley AG. Heat shock proteins, anti-heat shock protein reactivity and allograft rejection. Transplantation 2001; 71:1503-7.
9. Schaefer L, Babelova A, Kiss E et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 2005; 115:2223-33.
10. Moreth K, Brodbeck R, Babelova A et al. The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. J Clin Invest 2010; 120:4251-72.
11. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007; 81:1-5.
12. Wang S, Schmaderer C, Kiss E et al. Recipient Toll-like receptors contribute to chronic graft dysfunction by both MyD88- and TRIF-dependent signaling. Dis Model Mech 2010; 3:92-103.
13. Chen G, Li J, Ochani M et al. Bacterial endotoxin stimulates macrophages to release HMGB1 partly through CD14- and TNF-dependent mechanisms. J Leukoc Biol 2004; 76:994-1001.
14. Tejani A, Ho PL, Emmett L, Stablein DM. Reduction in acute rejections decreases chronic rejection graft failure in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Am J Transplant 2002; 2:142-7.
15. Matas AJ, Humar A, Payne WD, Gillingham KJ, Dunn DL, Sutherland DE, Najarian JS. Decreased acute rejection in kidney transplant recipients is associated with decreased chronic rejection. Ann Surg 1999; 230:493-8, discussion 498-500.
16. Hong F, Lee J, Song JW, Lee SJ, Ahn H, Cho JJ, Ha J, Kim SS. Cyclosporin A blocks muscle differentiation by inducing oxidative stress and inhibiting the peptidyl-prolyl-cis-trans isomerase activity of cyclophilin A: cyclophilin A protects myoblasts from cyclosporin A-induced cytotoxicity. FASEB J 2002; 16:1633-5.
17. Bansal S, Siddarth M, Chawla D, Banerjee BD, Madhu SV, Tripathi AK. Advanced glycation end products enhance reactive oxygen and nitrogen species generation in neutrophils in vitro. Mol Cell Biochem 2012; 361:289-96.
18. Fan J, Frey RS, Malik AB. TLR4 signaling induces TLR2 expression in endothelial cells via neutrophil NADPH oxidase. J Clin Invest 2003; 112:1234-43.
19. Yamamoto A, Ashihara E, Nakagawa Y et al. Allograft inflammatory factor-1 is overexpressed and induces fibroblast chemotaxis in the skin of sclerodermatous GVHD in a murine model. Immunol Lett 2011; 135:144-50.
20. Hellkvist J, Tufveson G, Gerdin B, Johnsson C. Characterization of fibroblasts from rejecting tissue: the hyaluronan production is increased. Transplantation 2002; 74:1672-7.
21. Chen J, John R, Richardson JA et al. Toll-like receptor 4 regulates early endothelial activation during ischemic acute kidney injury. Kidney Int 2011; 79:288-99.
22. Kang S, Lee SP, Kim KE, Kim HZ, Memet S, Koh GY. Toll-like receptor 4 in lymphatic endothelial cells contributes to LPS-induced lymphangiogenesis by chemotactic recruitment of macrophages. Blood 2009; 113:2605-13.
23. Neal MD, Leaphart C, Levy R et al. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. J Immunol 2006; 176:3070-9.
24. Eisinger K, Bauer S, Schaffler A, Walter R, Neumann E, Buechler C, Muller-Ladner U, Frommer KW. Chemerin induces CCL2 and TLR4 in synovial fibroblasts of patients with rheumatoid arthritis and osteoarthritis. Exp Mol Pathol 2011; 92:90-6.
25. Babelova A, Moreth K, Tsalastra-Greul W et al. Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J Biol Chem 2009; 284:24035-48.
26. Mariathasan S, Weiss DS, Newton K et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006; 440:228-32.
27. Ogura Y, Sutterwala FS, Flavell RA. The inflammasome: first line of the immune response to cell stress. Cell 2006; 126:659-62.
28. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237-41.
29. Williams CD, Antoine DJ, Shaw PJ et al. Role of the Nalp3 inflammasome in acetaminophen-induced sterile inflammation and liver injury. Toxicol Appl Pharmacol 2011; 252:289-97.
30. Duewell P, Kono H, Rayner KJ et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464:1357-61.
31. Mariathasan S, Monack DM. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 2007; 7:31-40.
32. Gasse P, Riteau N, Charron S et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care Med 2009; 179:903-13.
33. Rajamaki K, Lappalainen J, Oorni K, Valimaki E, Matikainen S, Kovanen PT, Eklund KK. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS ONE 2010; 5:e11765.
34. Ghaemi-Oskouie F, Shi Y. The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr Rheumatol Rep 2011; 13:160-6.
35. Piccini A, Carta S, Tassi S, Lasiglie D, Fossati G, Rubartelli A. ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL-1β and IL-18 secretion in an autocrine way. Proc Natl Acad Sci U S A 2008; 105:8067-72.
36. Eckle T, Krahn T, Grenz A et al. Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. Circulation 2007; 115:1581-90.
37. Wilhelm K, Ganesan J, Muller T et al. Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med 2010; 16:1434-8.
38. Idzko M, Hammad H, van Nimwegen M et al. Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat Med 2007; 13:913-9.
39. Netea MG, Nold-Petry CA, Nold MF et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1β in monocytes and macrophages. Blood 2009; 113:2324-35.
40. Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol 2004; 76:514-9.
41. Taflin C, Favier B, Baudhuin J et al. Human endothelial cells generate Th17 and regulatory T cells under inflammatory conditions. Proc Natl Acad Sci U S A 2011; 108:2891-6.
42. Benghiat FS, Charbonnier LM, Vokaer B, De Wilde V, Le Moine A. Interleukin 17-producing T helper cells in alloimmunity. Transplant Rev (Orlando) 2009; 23:11-8.
43. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007; 8:942-9.
44. H-17 responses. Nat Immunol 2008; 9:650-7.
45. H-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt. Nat Immunol 2008; 9:641-9.
46. Yuan X, Paez-Cortez J, Schmitt-Knosalla I et al. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med 2008; 205:3133-44.
47. Vanaudenaerde BM, De Vleeschauwer SI, Vos R et al. The role of the IL23/IL17 axis in bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant 2008; 8:1911-20.
48. Wilson NJ, Boniface K, Chan JR et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8:950-7.
49. Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 2006; 203:1685-91.
50. Rao DA, Tracey KJ, Pober JS. IL-1α and IL-1β are endogenous mediators linking cell injury to the adaptive alloimmune response. J Immunol 2007; 179:6536-46.
51. Min SI, Ha J, Park CG, Won JK, Park YJ, Min SK, Kim SJ. Sequential evolution of IL-17 responses in the early period of allograft rejection. Exp Mol Med 2009; 41:707-16.
52. Li L, Huang L, Vergis AL et al. IL-17 produced by neutrophils regulates IFN-γ-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. J Clin Invest 2010; 120:331-42.
53. Itoh S, Kimura N, Axtell RC et al. Interleukin-17 accelerates allograft rejection by suppressing regulatory T cell expansion. Circulation 2011; 124(11 Suppl.):S187-96.
54. Hennessy EJ, Parker AE, O'Neill LA. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 2010; 9:293-307.
55. Mastrangelo AM, Jeitner TM, Eaton JW. Oleic acid increases cell surface expression and activity of CD11b on human neutrophils. J Immunol 1998; 161:4268-75.
56. Smith CW, Marlin SD, Rothlein R, Toman C, Anderson DC. Cooperative interactions of LFA-1 and Mac-1 with intercellular adhesion molecule-1 in facilitating adherence and transendothelial migration of human neutrophils in vitro. J Clin Invest 1989; 83:2008-17.
57. Lange V, Renner A, Sagstetter MR, Lazariotou M, Harms H, Gummert JF, Leyh RG, Elert O. Heterotopic rat heart transplantation (Lewis to F344): early ICAM-1 expression after 8hours of cold ischemia. J Heart Lung Transplant 2008; 27:1031-5.
58. Jaakkola K, Jalkanen S, Kaunismaki K et al. Vascular adhesion protein-1, intercellular adhesion molecule-1 and P-selectin mediate leukocyte binding to ischemic heart in humans. J Am Coll Cardiol 2000; 36:122-9.
59. Marth T, Kelsall BL. Regulation of interleukin-12 by complement receptor 3 signaling. J Exp Med 1997; 185:1987-95.
60. Elzey BD, Sprague DL, Ratliff TL. The emerging role of platelets in adaptive immunity. Cell Immunol 2005; 238:1-9.
61. Kaneider NC, Kaser A, Tilg H, Ricevuti G, Wiedermann CJ. CD40 ligand-dependent maturation of human monocyte-derived dendritic cells by activated platelets. Int J Immunopathol Pharmacol 2003; 16:225-31.
62. Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006; 440:808-12.
63. Joffre O, Nolte MA, Sporri R, Reis e Sousa C. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev 2009; 227:234-47.
64. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12:991-1045.
65. Hayat A, Mukhopadhyay R, Radhika S, Sachdeva MS, Nada R, Joshi K, Sakhuja V, Jha V. Adverse impact of pretransplant polyoma virus infection on renal allograft function. Nephrology (Carlton) 2008; 13:157-63.
66. Hussain T, Burch M, Fenton MJ, Whitmore PM, Rees P, Elliott M, Aurora P. Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children. Circulation 2007; 115:1798-805.
67. Williams MA, Onami TM, Adams AB, Durham MM, Pearson TC, Ahmed R, Larsen CP. Cutting edge: persistent viral infection prevents tolerance induction and escapes immune control following CD28/CD40 blockade-based regimen. J Immunol 2002; 169:5387-91.
68. Delale T, Paquin A, Asselin-Paturel C et al. MyD88-dependent and -independent murine cytomegalovirus sensing for IFN-α release and initiation of immune responses in vivo. J Immunol 2005; 175:6723-32.
69. Xu D, Komai-Koma M, Liew FY. Expression and function of Toll-like receptor on T cells. Cell Immunol 2005; 233:85-9.
70. Yang J, Brook MO, Carvalho-Gaspar M et al. Allograft rejection mediated by memory T cells is resistant to regulation. Proc Natl Acad Sci U S A 2007; 104:19954-9.
71. + immunoregulatory T cells is antigen nonspecific. J Immunol 2000; 164:183-90.
72. Sutmuller RP, Morgan ME, Netea MG, Grauer O, Adema GJ. Toll-like receptors on regulatory T cells: expanding immune regulation. Trends Immunol 2006; 27:387-93.
73. Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M, Demengeot J. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med 2003; 197:403-11.
74. + T cells. Immunology 2007; 122:149-56.
75. + regulatory T cell function via innate TLR2 signaling. J Clin Invest 2006; 116:2022-32.
76. Sutmuller RP, den Brok MH, Kramer M et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest 2006; 116:485-94.
77. Land WG. The role of postischemic reperfusion injury and other nonantigen-dependent inflammatory pathways in transplantation. Transplantation 2005; 79:505-14.
78. Akao T, Takeyoshi I, Totsuka O et al. Effect of the free radical scavenger MCI-186 on pulmonary ischemia-reperfusion injury in dogs. J Heart Lung Transplant 2006; 25:965-71.
79. Suzuki F, Hashikura Y, Ise H, Ishida A, Nakayama J, Takahashi M, Miyagawa S, Ikeda U. MCI-186 (edaravone), a free radical scavenger, attenuates hepatic warm ischemia-reperfusion injury in rats. Transpl Int 2005; 18:844-53.
80. Fuller TF, Hoff U, Kong L et al. Cytoprotective actions of FTY720 modulate severe preservation reperfusion injury in rat renal transplants. Transplantation 2010; 89:402-8.
81. Bandhuvula P, Honbo N, Wang GY et al. S1P lyase (SPL): a novel therapeutic target for ischemia/reperfusion injury of the heart. Am J Physiol Heart Circ Physiol 2011; 300:H1753-61.
82. Kappos L, Antel J, Comi G et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355:1124-40.
83. Devouassoux G, Drouet C, Pin I, Brambilla C, Brambilla E, Colle PE, Pison C. Alveolar neutrophilia is a predictor for the bronchiolitis obliterans syndrome, and increases with degree of severity. Transpl Immunol 2002; 10:303-10.
84. Vos R, Vanaudenaerde BM, Ottevaere A et al. Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer? J Heart Lung Transplant 2010; 29:1358-68.
85. Federica M, Nadia S, Monica M, Alessandro C, Tiberio O, Francesco B, Mario V, Maria FA. Clinical and immunological evaluation of 12-month azithromycin therapy in chronic lung allograft rejection. Clin Transplant 2011; 25:E381-9.
86. Sugiyama K, Shirai R, Mukae H et al. Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells. Clin Exp Immunol 2007; 147:540-6.
87. Inci I, Erne B, Arni S et al. Prevention of primary graft dysfunction in lung transplantation by N-acetylcysteine after prolonged cold ischemia. J Heart Lung Transplant 2010; 29:1293-301.
88. Karlsson H, Nava S, Remberger M, Hassan Z, Hassan M, Ringden O. N-acetyl-l-cysteine increases acute graft-versus-host disease and promotes T-cell-mediated immunity in vitro. Eur J Immunol 2011; 41:1143-53.
89. Dave SH, Tilstra JS, Matsuoka K et al. Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol 2009; 86:633-43.
90. Kotsch K, Francuski M, Pascher A et al. Improved long-term graft survival after HO-1 induction in brain-dead donors. Am J Transplant 2006; 6:477-86.
91. Baan C, Peeters A, Lemos F et al. Fundamental role for HO-1 in the self-protection of renal allografts. Am J Transplant 2004; 4:811-8.
92. Gao Q, Ma LL, Gao X, Yan W, Williams P, Yin DP. TLR4 mediates early graft failure after intraportal islet transplantation. Am J Transplant 2010; 10:1588-96.
93. Yun TJ, Harning EK, Giza K et al. EC144, a synthetic inhibitor of heat shock protein 90, blocks innate and adaptive immune responses in models of inflammation and autoimmunity. J Immunol 2011; 186:563-75.
94. Polgar A, Falus A, Koo E et al. Elevated levels of synovial fluid antibodies reactive with the small proteoglycans biglycan and decorin in patients with rheumatoid arthritis or other joint diseases. Rheumatology (Oxford) 2003; 42:522-7.
95. McDonald B, Pittman K, Menezes GB et al. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 2010; 330:362-6.
96. Peng W, Cotrina ML, Han X et al. Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injury. Proc Natl Acad Sci U S A 2009; 106:12489-93.
97. Arslan F, Smeets MB, O'Neill LA et al. Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation 2010; 121:80-90.
98. Shimamoto A, Chong AJ, Yada M et al. Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation 2006; 114(1 Suppl.):I270-4.
99. Moser B, Szabolcs MJ, Ankersmit HJ, Lu Y, Qu W, Weinberg A, Herold KC, Schmidt AM. Blockade of RAGE suppresses alloimmune reactions in vitro and delays allograft rejection in murine heart transplantation. Am J Transplant 2007; 7:293-302.
100. Huang Y, Yin H, Han J et al. Extracellular HMGB1 functions as an innate immune-mediator implicated in murine cardiac allograft acute rejection. Am J Transplant 2007; 7:799-808.